10 completed, 2 unknown, 1 active not recruiting. 6 Phase 3, 3 Phase 2, 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 5, Unknown 1 |
| Phase 2 | 3 | Completed 3 |
| Phase 4 | 3 | Active not recruiting 1, Completed 1, Unknown 1 |
Follow Japanese Encephalitis Vaccines: new trials by email Literature Review of Japanese Encephalitis Vaccines trials Research Report on Japanese Encephalitis Vaccines
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis Japanese Encephalitis Vaccine (Vero Cell), Inactivated, Japanese Encephalitis Vaccine, Live - Japanese Encephalitis Vaccine | Phase 4 | Active not recruiting | Liaoning Chengda Biotechnology CO., LTD | 600 | 2023-11-11 | 2026-09-02 |
| Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province Japanese Encephalitis Vaccine (Vero Cell), Inactivated;, No prospective interventions - Japanese Encephalitis, Vaccine Preventable Disease | Phase 4 | Unknown | Zhejiang Provincial Center for Disease Control and Prevention | 712 | 2021-03-01 | 2022-11-15 |
| Purified Inactivated Japanese Encephalitis Vaccine Japanese Encephalitis Vaccine produced by IMBCAMS, Japanese Encephalitis Vaccine produced by Liaoning Chenda - Japanese Encephalitis Virus Disease | Phase 3 | Unknown | Chinese Academy of Medical Sciences | 1050 | 2015-09-01 | 2022-03-09 |
| Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj Japanese encephalitis vaccine - Japanese Encephalitis | Phase 4 | Completed | Boryung Pharmaceutical Co., Ltd | 94 | 2015-08-01 | 2017-02-06 |
| Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine CYD Dengue Vaccine, Japanese Encephalitis Vaccine - Dengue, Dengue Fever | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 90 | 2013-11-05 | 2022-03-24 |
| The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans Japanese Encephalitis vaccine, Yellow Fever vaccine - Yellow Fever, Encephalitis, Japanese | Phase 2 | Completed | Singapore General Hospital | 84 | 2013-10-01 | 2016-04-20 |
| A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Typhoid Vi Polysaccharide Vaccine, Yellow Fever Vaccine, Japanese Encephalitis Vaccine - Meningococcal Disease, Meningococcal Meningitis | Phase 3 | Completed | Novartis | 552 | 2011-11-01 | 2014-03-11 |
| Safety Surveillance After Immunization With IXIARO Japanese Encephalitis Virus vaccine, inactivated, adsorbed - Japanese Encephalitis | Completed | Valneva Austria GmbH | 20000 | 2011-03-01 | 2015-03-10 | |
| Novartis Vaccine and Diagnostics Carriage Trial Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ), MenACWY-CRM conjugate vaccine, Japanese Encephalitis vaccine - N. Meningitidis Carriage | Phase 3 | Completed | Novartis Vaccines | 2968 | 2010-09-01 | 2016-04-21 |
| Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling IC51 - Japanese Encephalitis | Phase 3 | Completed | Valneva Austria GmbH | 304 | 2008-09-01 | 2016-05-04 |
| Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines Japanese encephalitis vaccine, Japanese encephalitis vaccine (Acambis), Hepatitis A vaccine - Japanese Encephalitis, Hepatitis A | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1200 | 2008-08-01 | 2015-04-21 |
| Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28), Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28) - Japanese Encephalitis, Hepatitis A | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 300 | 2008-03-01 | 2014-10-02 |
| Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis. ChimeriVax-JE, Japanese Encephalitis vaccine, 0.9% Saline - Encephalitis, Japanese Encephalitis | Phase 3 | Completed | Sanofi | 2004 | 2005-10-01 | 2012-12-06 |
Encephalitis, Japanese (10) · Hepatitis A (2) · Yellow Fever (2) · Dengue (1) · Encephalitis (1) · Meningitis, Meningococcal (1) · Meningococcal Infections (1) · Rabies (1) · Severe Dengue (1) · Typhoid Fever (1) · Vaccine-Preventable Diseases (1)
Sanofi Pasteur, a Sanofi Company (3) · Valneva Austria GmbH (2) · Boryung Pharmaceutical Co., Ltd (1) · Chinese Academy of Medical Sciences (1) · Liaoning Chengda Biotechnology CO., LTD (1) · Novartis (1) · Novartis Vaccines (1) · Sanofi (1) · Singapore General Hospital (1) · Zhejiang Provincial Center for Disease Control and Prevention (1)
China (3) · United States (3) · Germany (2) · Thailand (2) · Australia (1) · Austria (1) · Czechia (1) · Philippines (1) · Singapore (1) · South Korea (1) · United Kingdom (1)
Evelyn Hatzenbichler (1) · HJ Jung, MD (1) · Huanyu Wang (1) · Jenny Low Guek Hong (1) · Katrin L Dubischar-Kastner, MSc (1) · Shaohong Yan (1) · Steven G Hull, MD (1)
PMID 20856164, PMID 20934459, PMID 22777096, PMID 24656175, PMID 24873986, PMID 25145775, PMID 25247300, PMID 25308927, PMID 25872531, PMID 27686833, PMID 27815383, PMID 29429815